Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)

Radiotherapy and Oncology

Volumn 100, Issue 1, 2011, Pages 76-85

  Baumann, M ^a   Herrmann, T ^a   Koch, R ^a   Matthiessen, W ^b   Appold, S ^a   Wahlers, B ^c   Kepka, L ^d   Marschke, G ^e   Feltl, D ^f   Fietkau, R ^g   Budach, V ^h   Dunst, J ⁱ   Dziadziuszko, R ^j   Krause, M ^a   Zips, D ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Technische Universität ^*  (Germany)

^c LUNGENKLINIK HEMER   (Germany)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e Stadtisches Klinikum Gorlitz gGmbH   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF ROSTOCK   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

more..

Author keywords

Accelerated radiotherapy; Non small cell lung cancer; Randomized trial; Time factor

Indexed keywords

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CONTINUOUS HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; DISTANT METASTASIS; DYSPHAGIA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 80051781895     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.06.031     Document Type: Article

References (43)

1. H.R. Withers, J.M. Taylor, and B. Maciejewski The hazard of accelerated tumor clonogen repopulation during radiotherapy Acta Oncol. 27 1988 131 146
2. J.F. Fowler Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment-continually rapid proliferation unmasked Radiother Oncol 22 1991 156 158
3. M. Baumann, M. Krause, and R. Hill Exploring the role of cancer stem cells in radioresistance Nat Rev Cancer 8 2008 545 554 (Pubitemid 351881850)
4. M. Baumann, M. Krause, H. Thames, K. Trott, and D. Zips Cancer stem cells and radiotherapy Int J Radiat Biol 2009 1 12
5. C. Petersen, D. Zips, and M. Krause Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation Int J Radiat Oncol Biol Phys 51 2001 483 493 (Pubitemid 32884296)
6. F. Hessel, M. Krause, and A. Helm Differentiation status of human squamous cell carcinoma xenografts does not appear to correlate with the repopulation capacity of clonogenic tumour cells during fractionated irradiation Int J Radiat Biol 80 2004 719 727 (Pubitemid 40126088)
7. F. Hessel, M. Krause, and C. Petersen Repopulation of moderately well-differentiated and keratinizing GL human squamous cell carcinomas growing in nude mice Int J Radiat Oncol Biol Phys 58 2004 510 518 (Pubitemid 38142478)
8. M. Baumann, W. Dorr, C. Petersen, and M. Krause Repopulation during fractionated radiotherapy: much has been learned, even more is open Int J Radiat Biol 79 2003 465 467 (Pubitemid 37311050)
9. T. Herrmann, and M. Baumann Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation Strahlenther Onkol 181 2005 65 76 (Pubitemid 40310798)
10. A. Allam, L.A. Perez, and P. Huang The effect of the overall treatment time of fractionated irradiation on the tumor control probability of a human soft tissue sarcoma xenograft in nude mice Int J Radiat Oncol Biol Phys 32 1995 105 111
11. H.D. Thames, D. Kuban, and L.B. Levy The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995 Radiother Oncol 96 2010 6 12
12. N.S. Bese, J. Hendry, and B. Jeremic Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation Int J Radiat Oncol Biol Phys 68 2007 654 661 (Pubitemid 46818766)
13. M. Saunders, S. Dische, A. Barrett, A. Harvey, D. Gibson, and M. Parmar Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee Lancet 350 1997 161 165 (Pubitemid 27303621)
14. M. Saunders, S. Dische, A. Barrett, A. Harvey, G. Griffiths, and M. Palmar Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee See comments Radiother Oncol 52 1999 137 148 (Pubitemid 29461081)
15. NICE. The diagnosis and treatment of lung cancer (update). In. http://www.nice.org.uk/nicemedia/live/11885/53195/53195.pdf, update 2011.
16. M.F. Jimenez, A. van Baardwijk, and H.J. Aerts Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis Radiother Oncol 97 2010 413 417
17. M. Baumann, S. Appold, C. Petersen, D. Zips, and T. Herrmann Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer Lung cancer 33 2001 S35 S45
18. M.I. Saunders, A. Rojas, and B.E. Lyn Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small- cell lung cancer Br J Cancer 78 1998 1323 1328 (Pubitemid 28495244)
19. M. Baumann, T. Herrmann, W. Matthiessen, R. Koch, K. Strelocke, and U. Paul CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-call bronchial carcinoma Strahlenther Onkol 173 1997 663 667 (Pubitemid 28082043)
20. K. Lang Langzeitergebnisse der CHARTWEL Pilotstudie bei Patienten mit nicht-kleinzelligem Bronchialkarzinom. In:Medizinische Fakultät Carl Gustav Carus 2010 Technische Universität Dresden
21. S.M. Bentzen, M.I. Saunders, and S. Dische From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome Clin Oncol (R Coll Radiol) 14 2002 372 381
22. D. Lehmann, H.K. Leetz, N. Hodapp, L. Voigtmann Dagger, T. Herrmann, and M. Baumann Physical and technical quality assurance in the CHARTWEL-Bronchus trial Strahlenther Onkol 179 2003 152 157 (Pubitemid 36313769)
23. S.M. Bentzen Dose-response relationships in radiotherapy M. Joiner, A.J. van der Kogel, Basic Clinical Radiobiology 2009 Edward Arnold London 56 67
24. M.I. Saunders, A. Rojas, B.E. Lyn, E. Wilson, and H. Phillips Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer Clin Oncol (R Coll Radiol) 14 2002 352 360
25. A.M. Rojas, B.E. Lyn, and E.M. Wilson Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer Cancer 107 2006 1321 1330 (Pubitemid 44452782)
26. P. Jenkins, S. Anderson, S. Wronski, and A. Ashton A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer Radiother Oncol 93 2009 396 401
27. C.P. Belani, W. Wang, and D.H. Johnson Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer J Clin Oncol 23 2005 3760 3767
28. D. Ball, J. Bishop, and J. Smith A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non- small cell lung cancer: final report of an Australian multi-centre trial [see comments] Radiother Oncol 52 1999 129 136 (Pubitemid 29461080)
29. D. De Ruysscher, M. Pijls-Johannesma, J. Vansteenkiste, A. Kester, I. Rutten, and P. Lambin Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann Oncol 17 2006 543 552
30. A.M. Brade, and I.F. Tannock Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol 24 2006 1020 1022 (Pubitemid 46638794)
31. L. Milas, T. Nakayama, and N. Hunter Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide Radiother Oncol 30 1994 247 253 (Pubitemid 24107519)
32. A. Auperin, C. Le Pechoux, and J.P. Pignon Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 2006 473 483 (Pubitemid 43329586)
33. A. Auperin, C. Le Pechoux, and E. Rolland Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
34. C. Dehing-Oberije, D. De Ruysscher, A. van Baardwijk, S. Yu, B. Rao, and P. Lambin The importance of patient characteristics for the prediction of radiation-induced lung toxicity Radiother Oncol 91 2009 421 426
35. M. Baumann, D. Zips, and S. Appold Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity Radiother Oncol 91 2009 279 281
36. D. De Ruysscher, A. Houben, and H.J. Aerts Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study Radiother Oncol 91 2009 415 420
37. H.J. Aerts, A.A. van Baardwijk, and S.F. Petit Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan Radiother Oncol 91 2009 386 392
38. A. Abramyuk, S. Tokalov, and K. Zophel Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 91 2009 399 404
39. M. MacManus, U. Nestle, and K.E. Rosenzweig Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007 Radiother Oncol 91 2009 85 94
40. S.M. Bentzen, M.I. Saunders, and S. Dische Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer Radiother Oncol 53 1999 219 226
41. S.M. Bentzen, J.Z. Skoczylas, and J. Bernier Quantitative clinical radiobiology of early and late lung reactions Int J Radiat Biol 76 2000 453 462 (Pubitemid 30232443)
42. A.T. Fernandes, J. Shen, and J. Finlay Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes Radiother Oncol 95 2010 178 184
43. N. Sanuki-Fujimoto, M. Sumi, and Y. Ito Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses Radiother Oncol 91 2009 433 437